Outcome of Pneumocystis Jirovecii pneumonia (PcP) in post-CAR-T patients with hematological malignancies
PcP can occur after different CAR-T product, and the long-term depletion of immune cells seems to be related to PcP. SMZ-TMP is effective in this setting. More real-world experience of CAR-T therapy is required to assess the incidence and outcome of PcP in this population.
Authors
- Cheng Zu (ORCID: https://orcid.org/0000-0003-3471-4338)
- Junwei Su (ORCID: https://orcid.org/0000-0001-7154-8928)
- Yetian Dong
- Wenxiao Li (ORCID: https://orcid.org/0000-0002-0144-918X)
- Mingming Zhang
- Shan Fu (ORCID: https://orcid.org/0000-0002-4970-7192)
- He Huang
- Jingjing Feng
- Ruimin Hong
- Yongxian Hu
Institutions
- Zhejiang Lab (CN)
- Zhejiang University-University of Edinburgh Institute (CN)
- National Center for Infectious Diseases (US)
- First Affiliated Hospital Zhejiang University (CN)
- State Key Laboratory of Diagnosis and Treatment of Infectious Diseases
- Zhejiang University (CN)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2024-10-13
- DOI
- https://doi.org/10.1186/s12879-024-09893-x
- Citations
- 3
- Primary Topic
- Pneumocystis jirovecii pneumonia detection and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- National Natural Science Foundation of China
- Zhejiang University
- National Key Research and Development Program of China